GMED vs. TFX, PODD, BAX, RMD, PEN, STVN, SOLV, GKOS, HAE, and MMSI
Should you be buying Globus Medical stock or one of its competitors? The main competitors of Globus Medical include Teleflex (TFX), Insulet (PODD), Baxter International (BAX), ResMed (RMD), Penumbra (PEN), Stevanato Group (STVN), Solventum (SOLV), Glaukos (GKOS), Haemonetics (HAE), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Teleflex (NYSE:TFX) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.
Teleflex has higher revenue and earnings than Globus Medical. Teleflex is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Teleflex has a net margin of 9.82% compared to Teleflex's net margin of 3.51%. Globus Medical's return on equity of 14.78% beat Teleflex's return on equity.
In the previous week, Teleflex had 3 more articles in the media than Globus Medical. MarketBeat recorded 15 mentions for Teleflex and 12 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.81 beat Teleflex's score of 0.73 indicating that Teleflex is being referred to more favorably in the media.
Teleflex has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Globus Medical has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Globus Medical received 27 more outperform votes than Teleflex when rated by MarketBeat users. Likewise, 67.79% of users gave Globus Medical an outperform vote while only 59.54% of users gave Teleflex an outperform vote.
Teleflex presently has a consensus price target of $261.75, suggesting a potential upside of 20.27%. Globus Medical has a consensus price target of $66.50, suggesting a potential upside of 3.26%. Given Globus Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Teleflex is more favorable than Globus Medical.
95.6% of Teleflex shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 1.4% of Teleflex shares are held by company insiders. Comparatively, 24.3% of Globus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Teleflex beats Globus Medical on 12 of the 17 factors compared between the two stocks.
Get Globus Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Globus Medical Competitors List
Related Companies and Tools
